Two years of empagliflozin treatment in patients with chronic kidney disease slowed progression and reduced cardiovascular risk. Findings from a 2-year post-trial follow-up are summarized in a ...

Jardiance is also authorised to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. According to the FDA, heart disease impacts more than ...